×
RAPS Learning Portal will be under maintenance on 12 June 2026 between 10 PM - 12 AM ET. Learning Portal functionality and profile access may be unavailable during this window.
We apologize for any inconvenience caused during this time.

 

3 March 2021
by Kevin Hennegan

Understanding the purpose of an IND

Opening an Investigational New Drug (IND) application dossier can allow a sponsor to take advantage of the FDA’s drug development expertise and ensure the development program will meet the agency’s expectations at the time of the marketing application.

In a webinar replay, Veristat experts explore the minimum required content for an IND submission and the strategic considerations for developing more than the minimum necessary data before filing an IND.

View the webinar replay to help you better understand:
  • Drug development overview
  • Purpose of an IND
  • When do you have enough data?
  • Value of a pre-IND meeting
Kevin Hennegan is a senior regulatory strategist at Veristat.